Rimegepant

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 284 publications

Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study.

Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study.

Journal: Pain management

Published: April 03, 2026

A pilot, randomized, placebo-controlled trial of rimegepant on visceral sensation and symptoms in nonconstipation IBS pain.

A pilot, randomized, placebo-controlled trial of rimegepant on visceral sensation and symptoms in nonconstipation IBS pain.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Published: February 04, 2026

Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.

Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.

Journal: Pain physician

Published: February 02, 2026

Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives.

Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives.

Journal: Expert review of neurotherapeutics

Published: January 24, 2026

Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.

Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: January 09, 2026

Migraine-induced cochlear injury triggers ZBP1-mediated PANoptosis via CGRP signaling.

Migraine-induced cochlear injury triggers ZBP1-mediated PANoptosis via CGRP signaling.

Journal: The journal of headache and pain

Published: January 08, 2026

Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine.

Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine.

Journal: Headache

Published: December 23, 2025

Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison.

Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison.

Journal: Expert review of neurotherapeutics

Published: December 18, 2025

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.

Journal: The journal of headache and pain

Published: December 17, 2025

Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System.

Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: December 09, 2025

Identification and validation of NETs-associated biomarkers in osteoporosis with diabetes.

Identification and validation of NETs-associated biomarkers in osteoporosis with diabetes.

Journal: Scientific reports

Published: December 04, 2025

Biodistribution of atogepant and rimegepant in mouse peripheral and central structures of relevance to migraine pathogenesis.

Biodistribution of atogepant and rimegepant in mouse peripheral and central structures of relevance to migraine pathogenesis.

Journal: Cephalalgia : an international journal of headache

Published: November 28, 2025

Showing 1-12 of 284

Last Updated: 04/28/2026